AKTX

Akari TherapeuticsF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$18.00

+63.5% vs current

Most likely

Base case

45%

Probability

Target price

$7.50

-31.9% vs current

B-

Bear case

30%

Probability

Target price

$3.00

-72.8% vs current

AI sentiment snapshot

Latest data as of 2026-06-26

AI commentary

Official-company newsflow turned more constructive in April-June 2026 because Akari released multiple preclinical, patent, and partnership updates, but the burst is still mostly issuer-driven and not matched by deep analyst revision evidence. Social coverage in the packet is absent, sell-side coverage appears thin, and the deterministic prior remains negative, so this reads as a monitoring story rather than a high-conviction sentiment improvement.

RankAlpha Sentiment Codex - 2026-06-26

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-07-15eventJuly 2026 final private-placement tranche and warrant overhangHigh impact

The May 2026 financing is structured in three closings, with the third closing expected on or about 2026-07-15; the related Series H/I/J warrants and placement-agent ADSs remain subject to shareholder approval, and resale registration is due after the final closing, so balance-sheet relief comes with continued dilution/overhang risk [#8-K-2026-05-22].

2026-12-31catalystPlatform validation from WuXi XDC and IP expansion could improve partnering oddsHigh impact

Akari said its WuXi XDC partnership should support development acceleration, while May 2026 patent expansion strengthened PH1 payload protection in major markets; if those pieces translate into faster IND-enabling work or external partnering, they could modestly improve credibility for a subscale platform story [#PR-2026-04-06] [#PR-2026-05-12].

2027-06-30catalystAKTX-101 must convert preclinical momentum into an IND-ready clinical pathHigh impact

Company releases in April-June 2026 highlighted differentiated preclinical AKTX-101/PH1 activity, ASCO visibility, and a planned first-in-human Phase 1 start by mid-2027, but the thesis still depends on successful IND-enabling execution rather than clinical proof today [#PR-2026-04-20] [#PR-2026-04-21] [#PR-2026-06-04].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-26 • Updated nightlySource: Internal modelMethodology